Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Cipla reports a significant Q4 profit rise despite concerns over US tariffs and drug price orders.

flag Cipla, an Indian pharmaceutical company, reported a 30% rise in Q4 net profit to Rs 1,222 crore and a 9% increase in revenue to Rs 6,730 crore. flag The company's CEO, Umang Vohra, stated that potential US tariffs and Trump's order on drug prices are not expected to have an immediate impact on Cipla. flag The company's board approved a dividend of Rs 16 per share, marking its 90th anniversary. flag For FY25, Cipla saw a 28% increase in net profit to Rs 5,272 crore.

12 Articles

Further Reading